Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Since 2004, metastatic breast cancer patients pretreated with anthracyclines, taxanes, and capecitabine have been treated in our institution with a combination of mitomycin C, methotrexate, and VP-16 (VMM). We report in this study a retrospective analysis of the activity and safety of the VMM combination.
Patients were treated with a combination of VP-16 (100 mg/m2 on day 1), mitomycin C (MMC, 10 mg/m2 on day 1), and methotrexate (MTX, 12.5 mg/m2 twice a day on day 2 and 3) in a 21-day cycle.
Seventy-five patients were treated. Median age was 48 years. A total of 256 cycles were administered. Median relative dose intensities were 0.87, 0.87, and 0.95 for VP-16, MMC, and MTX, respectively. Objective response rate was 31%, with a clinical benefit rate of 47%. Median response duration was 5.8 months. Median disease stabilization duration was 9.1 months. Median progression-free survival (PFS) was 4.2 months with a 14% 1-year PFS rate. Median overall survival (OS) was 6.2 months, with a 25% 1-year OS rate. Myelosuppression was the most common toxicity. The most commonly reported extra-hematological adverse event (AE) was fatigue. Emesis and alopecia were rarely reported.
This combination appears to be effective and well tolerated in this heavily pretreated metastatic breast cancer population.
- Overmoyer B. Options for the treatment of patients with taxane-refractory metastatic breast cancer. Clin Breast Cancer. 2008;8(Suppl 2):S61–70. CrossRef
- Perez EA. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat. 2009;114(2):195–201. CrossRef
- Barnett CM. Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer. Pharmacotherapy. 2009;29(12):1482–90. CrossRef
- Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005;90(3):215–21. CrossRef
- O’Shaughnessy JA, Clark RS, Blum JL, Mennel RG, Snyder D, Ye Z, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer. 2005;6(2):143–9. CrossRef
- Brodowicz T, Kostler WJ, Moslinger R, Tomek S, Vaclavik I, Herscovici V, et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast. 2000;9(6):338–42. CrossRef
- Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407–14. CrossRef
- Onyenadum A, Gogas H, Markopoulos C, Bafaloukos D, Aravantinos G, Mantzourani M, et al. Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. J Chemother. 2007;19(5):582–9.
- Jara-Sanchez C, Martin M, Garcia-Saenz JA, Barnada A, Fernandez-Aramburo A, Lopez-Vega JM, et al. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group. Clin Breast Cancer. 2003;3(6):399–404. CrossRef
- van Oosterom AT, Powles TJ, Hamersma E, Smith IE, Engelsman E. A phase II study of mitomycin C in refractory advanced breast cancer. A multi-centre pilot study. Eur J Cancer. 1980;Suppl 1:275–6.
- Hortobagyi GN. Mitomycin: its evolving role in the treatment of breast cancer. Oncology. 1993;50(Suppl 1):1–8. CrossRef
- Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005;330(7485):217. CrossRef
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717. CrossRef
- Schell FC, Yap HY, Hortobagyi GN, Issell B, Esparza L. Phase II study of VP16–213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol. 1982;7(2–3):223–5.
- Pouillart P, Palangie T, Jouve M, Garcia-Giralt E, Magdelenat H. Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author’s transl). Bull Cancer. 1979;66(5):485–90.
- Tanabe M, Ito Y, Tokudome N, Sugihara T, Miura H, Takahashi S, et al. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer. 2009;16(4):301–6. CrossRef
- Powles TJ, Jones AL, Judson IR, Hardy JR, Ashley SE. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer. 1991;64(2):406–10. CrossRef
- Jodrell DI, Smith IE, Mansi JL, Pearson MC, Walsh G, Ashley S, et al. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. Br J Cancer. 1991;63(5):794–8. CrossRef
- Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury GJ, Mehta J, et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer. 2000;83(1):91–4. CrossRef
- Schell FC, Yap HY, Blumenschein G, Valdivieso M, Bodey G. Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep. 1982;66(8):1641–3.
- Zubrod C, Schneiderman M, Frei EJ. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard an triethylene thiophosphoramide. J Chron Dis. 1960;11:7–33. CrossRef
- World Health Organization. WHO handbook for reporting the results of cancer treatment. Geneva;1979.
- Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457–81. CrossRef
- Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8(12):1935–7.
- Massacesi C, La Cesa A, Marcucci F, Pilone A, Rocchi MB, Zepponi L, et al. Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology. 2006;70(4):294–300. CrossRef
- Smith IE, Powles TJ. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer. Oncology. 1993;50(Suppl 1):9–15. CrossRef
- Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27(18):2954–61. CrossRef
- Ito Y, Osaki Y, Tokudome N, Sugihara T, Takahashi S, Iwase T, et al. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine. Breast Cancer. 2009;16(2):126–31. CrossRef
- Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study
Volume 19, Issue 1 , pp 16-22
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Breast cancer
- Mitomycin C
- Industry Sectors
- Author Affiliations
- 1. Department of Medical Oncology, CRLC Val d’Aurelle, 208 rue des Apothicaires, 34298, Montpellier Cedex 5, France
- 2. Department of Biostatistics, CRLC Val d’Aurelle, Montpellier, France
- 3. Oncopharmacology Department, CRLC Val d’Aurelle, Montpellier, France